Fact-finding survey on assisted reproductive technology in Japan.
Japan
add-ons
assisted reproductive technology
health workforce
medical supplies
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
31
07
2023
accepted:
15
08
2023
medline:
6
11
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
ppublish
Résumé
In anticipation of the future development of assisted reproductive technology (ART) and to smoothly introduce new technology, it is necessary to understand the current staffing status of the medical system and the current state of treatment, as well as the status of in vitro fertilization add-ons, where the need for insurance coverage is currently a matter of debate. ART facilities in Japan were surveyed (437 valid responses, response rate: 71%). Current staffing status of the medical system, implementation rates of ART, add-on treatments, and medical supplies were investigated. Despite the abundance of embryologists, nurses, and obstetricians and gynecologists in facilities, the majority of facilities lacked counselors, anesthesiologists, and other essential medical professionals. Conventional ovarian stimulation was widely adopted (median 120 [interquartile range 60-300] cycles), followed by mild ovarian simulation (60 [30-200]). Additionally, freeze-thaw embryo transfer cycles (300 [120-750]) were performed more frequently than fresh embryo transfer cycles (30 [30-60]). Among the add-ons, assisted hatching (85.1%), chronic endometritis examination (77.2%) and treatment (76.9%), artificial oocyte activation (67.3%), endometrial receptivity analysis (64.2%), and endometrial microbiome analysis (58.9%) were relatively widely employed. The implementation of frozen-thawed embryo transfer cycles, freeze-all strategies, and add-on treatments have become popular and widely accepted despite the lack of robust evidence regarding their safety and efficacy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2593-2601Informations de copyright
© 2023 The Authors. Journal of Obstetrics and Gynaecology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Obstetrics and Gynecology.
Références
Outline of Health, Labour and Welfare Statistics. Director-general for statistics, information policy and industrial relations. Japan: Ministry of Health, Labour and Welfare; 2021.
Imai Y, Endo M, Kuroda K, Tomooka K, Ikemoto Y, Sato S, et al. Risk factors for resignation from work after starting infertility treatment among Japanese women: Japan-female employment and mental health in assisted reproductive technology (J-FEMA) study. Occup Environ Med. 2020;78(6):426-432.
Katagiri Y, Jwa SC, Kuwahara A, Iwasa T, Ono M, Kato K, et al. Assisted reproductive technology in Japan: a summary report for 2020 by the ethics Committee of the Japan Society of obstetrics and gynecology. Reprod Med Biol. 2023;22(1):e12494.
National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). Assisted Reproductive Technology (ART) Report National ART Success Rates. Atlanta, GA: Centers for Disease Control and Prevention; 2019.
Yamada M, Ishikawa T, Iwasa T, Oishi H, Osuka S, Oka K, et al. Guidelines for reproductive medicine in Japan. Reprod Med Biol. 2022;21(1):e12483.
Masuda H, Maruyama T, Hiratsu E, Yamane J, Iwanami A, Nagashima T, et al. Noninvasive and real-time assessment of reconstructed functional human endometrium in NOD/SCID/gamma c(null) immunodeficient mice. Proc Natl Acad Sci U S A. 2007;104(6):1925-1930.
Pilot national fertility patient survey. Human Fertilisation and Embryology Authority. 2018.
Lensen S, Hammarberg K, Polyakov A, Wilkinson J, Whyte S, Peate M, et al. How common is add-on use and how do patients decide whether to use them? A national survey of IVF patients. Hum Reprod. 2021;36(7):1854-1861.
Boivin J, Appleton TC, Baetens P, Baron J, Bitzer J, Corrigan E, et al. Guidelines for counselling in infertility: outline version. Hum Reprod. 2001;16(6):1301-1304.
Domar A, Vassena R, Dixon M, Costa M, Vegni E, Collura B, et al. Barriers and factors associated with significant delays to initial consultation and treatment for infertile patients and partners of infertile patients. Reprod Biomed Online. 2021;43(6):1126-1136.
Ombelet W, van Eekelen R, McNally A, Ledger W, Doody K, Farquhar C. Should couples with unexplained infertility have three to six cycles of intrauterine insemination with ovarian stimulation or in vitro fertilization as first-line treatment? Fertil Steril. 2020;114(6):1141-1148.
Scotti M. Paying to treat infertility: coverage varies widely across Canada. 2016.
Jain T, Harlow BL, Hornstein MD. Insurance coverage and outcomes of in vitro fertilization. N Engl J Med. 2002;347(9):661-666.
Exploring and Unlocking Real Key Asian insights in family building dreams! 2022.
Marcus D, Marcus A, Johnson A, Marcus S. Infertility treatment: when is it time to give up? An Internet-based survey. Hum Fertil (Camb). 2011;14(1):29-34.
FY2020 Research Project for the Promotion of Support for Children and Child-rearing. Survey research on the reality of infertility treatment, Final Report. Tokyo: Nomura Research Institute, Ltd; 2021.
Is In Vitro Fertilization Expensive? ReproductiveFacts.org 2020. American Society for Reproductive Medicine.
Research report on financial support for infertility treatment in foreign countrie. Nomura Research Institute, Ltd.
Boulet SL, Crawford S, Zhang Y, Sunderam S, Cohen B, Bernson D, et al. Embryo transfer practices and perinatal outcomes by insurance mandate status. Fertil Steril. 2015;104(2):403-9.e1.
Macklon NS, Ahuja KK, Fauser B. Building an evidence base for IVF ‘add-ons’. Reprod Biomed Online. 2019;38(6):853-856.
Medical Service Fertility Treatment. Korea Health Industry Developmental Institute.
Specific Treatment Support Project for Those Suffering from Infertility. Ministry of Health, Labour and Welfare.
National Patient Survey report. Human Fertilisation & Embryology Authority 2022.